Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 9Endocrine 7NET 5Tumor-Agnostic 1Sarcoma 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Diarrhea 1Colorectal Neoplasms 1

Interventions

Doxorubicin 40Radiotherapy 30Ifosfamide 28Vincristine 27Cyclophosphamide 24Imatinib Mesylate 20Etoposide 20Dactinomycin 14Radiation 13Filgrastim 11Temozolomide 9Sunitinib 9Trabectedin 8Methotrexate 8Specimen Handling 7Magnetic Resonance Spectroscopy 6Granulocyte Colony-Stimulating Factor 6Chemotherapy, Adjuvant 6pazopanib 5nilotinib 5Zoledronic Acid 5Neoadjuvant Therapy 5Irinotecan 5Cisplatin 5Carboplatin 5X-Rays 4Vinorelbine 4Topotecan 4Surgical Procedures, Operative 4Procarbazine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Octreotide × Sarcoma × Clear all
NCT00033605 2016-07-13

Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis

Alliance for Clinical Trials in Oncology

Phase 3 Completed
130 enrolled
GastrointestinalGenitourinaryGynecologicSarcoma

Uterine Cervical Neoplasms, Diarrhea, Fallopian Tube Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vaginal Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡